159 related articles for article (PubMed ID: 36715286)
21. Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature.
Kosche C; Stout M; Sosman J; Lukas RV; Choi JN
Melanoma Res; 2020 Jun; 30(3):313-316. PubMed ID: 31567590
[TBL] [Abstract][Full Text] [Related]
22. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
[TBL] [Abstract][Full Text] [Related]
23. [Life-threatening flare of an underlying «paraneoplastic» dermatomyositis in a patient with lung adenocarcinoma treated with anti-PD-1 pembrolizuma].
Chauveheid F; von Frenckell C; Colin G; Deflandre E; Piette Y; Duysinx B; Bianchi E; Malaise M; Malaise O
Rev Med Liege; 2022 Jul; 77(7-8):462-467. PubMed ID: 35924504
[TBL] [Abstract][Full Text] [Related]
24. Myositis and myasthenia during nivolumab administration for advanced lung cancer: a case report and review of the literature.
Veccia A; Kinspergher S; Grego E; Peterlana D; Berti A; Tranquillini E; Caffo O
Anticancer Drugs; 2020 Jun; 31(5):540-544. PubMed ID: 32011360
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
[TBL] [Abstract][Full Text] [Related]
26. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature.
Messer A; Drozd B; Glitza IC; Lu H; Patel AB
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941716
[TBL] [Abstract][Full Text] [Related]
27. Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an "autoimmune tumor marker": A case report.
Karino K; Fujieda Y; Kawamura T; Abe N; Shimoyama S; Kono M; Kato M; Yasuda S; Atsumi T
Medicine (Baltimore); 2018 Dec; 97(49):e13563. PubMed ID: 30544475
[TBL] [Abstract][Full Text] [Related]
28. Transcriptional intermediary factor 1 (TIF1) and anti-TIF1γ antibody-positive dermatomyositis.
Kotobuki Y; Tonomura K; Fujimoto M
Immunol Med; 2021 Mar; 44(1):23-29. PubMed ID: 32649853
[TBL] [Abstract][Full Text] [Related]
29. Nivolumab-induced Myositis and Myocarditis with Positive Anti-titin Antibody and Anti-voltage-gated Potassium Channel Kv1.4 Antibody.
Ono R; Iwai Y; Yamazaki T; Takahashi H; Hori Y; Fukushima K; Saotome T
Intern Med; 2022 Oct; 61(19):2973-2979. PubMed ID: 35314545
[TBL] [Abstract][Full Text] [Related]
30. Serum levels of anti-transcriptional intermediary factor 1-γ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis.
Zhang L; Yang H; Yang H; Liu H; Tian X; Jiang W; Peng Q; Wang G; Lu X
Semin Arthritis Rheum; 2022 Aug; 55():152011. PubMed ID: 35489170
[TBL] [Abstract][Full Text] [Related]
31. Anti-TIF1γ antibody-positive dermatomyositis in a 15-year-old boy with Epstein-Barr virus-related nasopharyngeal cancer receiving nivolumab.
Asano R; Shinoda K; Tsuda R; Hounoki H; Kawataka M; Makino T; Imura J; Hamaguchi Y; Tobe K
Rheumatology (Oxford); 2021 Jun; 60(6):e197-e199. PubMed ID: 33367923
[No Abstract] [Full Text] [Related]
32. Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese community hospital.
Suga T; Oiwa H; Ishida M; Iwamoto Y
Clin Rheumatol; 2022 Sep; 41(9):2803-2808. PubMed ID: 35399148
[TBL] [Abstract][Full Text] [Related]
33. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients.
Ogawa-Momohara M; Muro Y; Mitsuma T; Katayama M; Yanaba K; Nara M; Kakeda M; Kono M; Akiyama M
Clin Exp Rheumatol; 2018; 36(6):990-995. PubMed ID: 29745874
[TBL] [Abstract][Full Text] [Related]
34. Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature.
Guerra NL; Matas-García A; Serra-García L; Morgado-Carrasco D; Padrosa J; Aldecoa I; Duque Y; Casal-Dominguez M; Muñoz-Braceras S; Aranega R; Moreno-Lozano P; Cantó-Santos J; Garrabou G; Ruiz-Ortiz E; Trallero-Araguas E; Selva-O'Callaghan A; Grau JM; Puig S; Torres-Ruiz J; Mammen AL; Fernandez IP; Milisenda JC
Autoimmun Rev; 2023 Aug; 22(8):103375. PubMed ID: 37321468
[TBL] [Abstract][Full Text] [Related]
35. Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma.
Yamaguchi Y; Aso M; Nagasawa H; Wada M
Intern Med; 2021 Sep; 60(18):3025-3029. PubMed ID: 33776010
[TBL] [Abstract][Full Text] [Related]
36. Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis.
Pinal-Fernandez I; Ferrer-Fabregas B; Trallero-Araguas E; Balada E; Martínez MA; Milisenda JC; Aparicio-Español G; Labrador-Horrillo M; Garcia-Patos V; Grau-Junyent JM; Selva-O'Callaghan A
Rheumatology (Oxford); 2018 Feb; 57(2):388-396. PubMed ID: 29149307
[TBL] [Abstract][Full Text] [Related]
37. Clinical features of anti-transcription intermediary factor 1γ (TIF1γ)-positive dermatomyositis with internal malignancy and investigation of the involvement of TIF1γ expression in tumors in the pathogenesis of cancer-associated dermatomyositis.
Motegi SI; Sekiguchi A; Ikeuchi H; Sakairi T; Ogawa H; Fujii T; Sohda M; Yajima T; Ida S; Takayasu Y; Shimoda Y; Hiromura K; Saeki H; Shirabe K; Chikamatsu K; Yokoo H; Oyama T; Ishikawa O
J Dermatol; 2020 Dec; 47(12):1395-1402. PubMed ID: 32734678
[TBL] [Abstract][Full Text] [Related]
38. Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study.
Dani L; Holmqvist M; Martínez MA; Trallero-Araguas E; Dastmalchi M; Svensson J; Labrador-Horrillo M; Selva-O'Callaghan A; Lundberg IE
Clin Exp Rheumatol; 2020; 38(1):67-73. PubMed ID: 31365334
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3.
Chin K; Yamamoto S; Takahashi M; Kadowaki S; Kubota Y; Amanuma Y; Okada M; Kanda M; Kimura Y; Nogi Y; Arimitsu Y; Kitagawa Y
Esophagus; 2023 Apr; 20(2):302-308. PubMed ID: 36564602
[TBL] [Abstract][Full Text] [Related]
40. Association of Anti-Transcription Intermediary Factor 1γ Antibodies With Paraneoplastic Rheumatic Syndromes Other Than Dermatomyositis.
Venalis P; Selickaja S; Lundberg K; Rugiene R; Lundberg IE
Arthritis Care Res (Hoboken); 2018 Apr; 70(4):648-651. PubMed ID: 28704599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]